Consistent with the network pharmacology results, the RT-PCR experiments showed significant downregulation of JUN, HSP90AA1, HDAC1, and CDK1 expression by TGT, highlighting their potential significance as targets in the anti-osteosarcoma mechanism of TGT. The gene discussed is CDK1; the disease is osteosarcoma.